Back to Market Feed

Strength

50; 200; 25 mg/1; mg/1; mg/1

NDC

61958250101

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Approval Type

New Drug (NDA)

FDA Application

NDA210251

On Market Since

2/7/2018

Pharmacological Classes

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Nucleoside Reverse Transcriptase Inhibitors
Nucleoside Reverse Transcriptase Inhibitors
Nucleosides
Nucleosides

Price History

1W

0.0%

1M

-0.0%

3M

+0.0%

6M

+0.0%

1Y

+0.3%

3Y

+11.5%

5Y

+24.8%

All

+44.3%

Generic Alternatives

1 alternative • Same active ingredient

BIKTARVY 50-200-25 MG TABLET
Brand
61958250103•Gilead Sciences, Inc.
$136.7317

Related Drugs

Same classification

EPIVIR 10 MG/ML ORAL SOLN
Brand
49702020548•ViiV Healthcare Company
$0.4452
per ML
ZIAGEN 20 MG/ML SOLUTION
Brand
49702022248•ViiV Healthcare Company
$0.5865
per ML
EPIVIR 150 MG TABLET
Brand
49702020318•ViiV Healthcare Company
$6.6144
per EA
IMURAN 50 MG TABLET
Brand
54766059010•Sebela Pharmaceuticals Inc.
$8.8907
per EA
INTELENCE 100 MG TABLET
Brand
59676057001•Janssen Products LP
$10.9213
per EA
EPIVIR 300 MG TABLET
Brand
49702020413•ViiV Healthcare Company
$13.2940
per EA
COMBIVIR TABLET
Brand
49702020218•ViiV Healthcare Company
$14.3948
per EA
EMTRIVA 200 MG CAPSULE
Brand
61958060101•Gilead Sciences, Inc.
$17.4370
per EA
INTELENCE 200 MG TABLET
Brand
59676057101•Janssen Products LP
$24.2861
per EA
VIREAD 300 MG TABLET
Brand
61958040101•Gilead Sciences, Inc.
$40.7318
per EA